EP 1085872 A1 20010328 - INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B
Title (en)
INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B
Title (de)
INHIBITOREN DES NFKAPPA-BTRANSKRIPTIONSFAKTORS
Title (fr)
INHIBITEURS DU FACTEUR DE TRANSCRIPTION NF-$g(k)B
Publication
Application
Priority
- US 9913897 W 19990618
- US 9001698 P 19980619
Abstract (en)
[origin: WO9965495A1] The present invention provides amino-indanone inhibitors of transcription factor NF- kappa B and pharmaceutically acceptable salts, hydrates and solvates thereof, pharmaceutical compositions of such compounds, and methods for treating diseases in which activation of NF- kappa B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF- kappa B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and acute dermatosis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins disease; and certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.
IPC 1-7
A61K 31/535; A61K 31/495; A61K 31/445; A61K 31/40; A61K 31/135
IPC 8 full level
A61K 31/135 (2006.01); A61K 31/4453 (2006.01); A61K 31/4462 (2006.01); A61K 31/5375 (2006.01); A61P 1/04 (2006.01); C07D 295/10 (2006.01); A61P 9/00 (2006.01); A61P 9/02 (2006.01); A61P 9/10 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)
CPC (source: EP KR)
A61K 31/135 (2013.01 - EP); A61K 31/4462 (2013.01 - EP); A61K 31/535 (2013.01 - KR); A61K 31/5375 (2013.01 - EP); A61P 1/04 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/02 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/04 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/10 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 39/00 (2018.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9965495 A1 19991223; AR 019871 A1 20020320; AU 4699699 A 20000105; BR 9911151 A 20010306; CA 2335293 A1 19991223; CN 1306428 A 20010801; CO 5080752 A1 20010925; CZ 20004760 A3 20010815; EP 1085872 A1 20010328; EP 1085872 A4 20030416; HU P0102492 A2 20011128; IL 140324 A0 20020210; JP 2002518333 A 20020625; KR 20010052990 A 20010625; NO 20006452 D0 20001218; NO 20006452 L 20010216; PL 345577 A1 20011217; TR 200003779 T2 20010621; ZA 200007448 B 20011212
DOCDB simple family (application)
US 9913897 W 19990618; AR P990102952 A 19990618; AU 4699699 A 19990618; BR 9911151 A 19990618; CA 2335293 A 19990618; CN 99807572 A 19990618; CO 99037918 A 19990617; CZ 20004760 A 19990618; EP 99930459 A 19990618; HU P0102492 A 19980618; IL 14032499 A 19990618; JP 2000554375 A 19990618; KR 20007014385 A 20001218; NO 20006452 A 20001218; PL 34557799 A 19990618; TR 200003779 T 19990618; ZA 200007448 A 20001213